MAZE · Maze Therapeutics, Inc.
$28.64
-0.94 (-3.18%)
At close · Aug 27
Market Cap
$1.65B
Shares
55.55M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$29.58
Open$30.26
Day$29.33–30.40
52W close$13.87–51.84
Avg vol 30d359K
Short int6.0M · 10.8% float · 16.2d
Short vol74%
Last earningsMar 25, 2026
DataJan 2025–Aug 2026
Filing10-Q · Aug 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−14%
below
Price vs 50-day avg
+4%
above
RSI (14)
56
neutral
MACD trend
Positive
52-week position
41%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+8%
trailing
6-month return
−35%
trailing
YTD return
−29%
this year
Relative strength
−47%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $28 › 200d $34 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +39 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.78% of float · ▲ +5.5% MoM · 16.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
162 holders — mid 1-yr range
Squeeze score
82
high risk · 0–100
Fundamentals
EPS growth
−344%
Y/Y
Free cash flow
$-112.7M
Balance sheet
$189.2M
net cash
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−14%
Bearish
Price vs 50-day avg
+4%
Bullish
RSI (14)
56
Neutral
MACD trend
Positive
Bullish
52-week position
41%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $28 › 200d $34 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +39 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.78% of float · ▲ +5.5% MoM · 16.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
162 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $14
Now $30 · 41%
Range high $52
vs 200-day avg -14%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MAZE
this stock
Maze Therapeutics, Inc.
|
$1.65B | -28.6% | — | — | 10.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MAZE | -0.6% | +8.5% | -34.7% | +9.9% | -28.6% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | -0.2% | +3.5% | -47.1% | +7.3% | -40.9% |
Key facts
CIK
1842295
CUSIP
578784100
13F (30d)
151 filings
150 filers
Visit website
Investor relations